UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

Archives

2026
- February
2025
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2024
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2023
- December
- November
- October
- September
- August
- July
- June
- April
- March
- February
- January
2022
- December
- November
- September
- August
- June
- May
- March
- February
- January
2021
- December
- November
- October
- September
- August
- May
- April
- February

Oct

16 Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Read More Share:

|

Sep

29 New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Read More Share:

|

Aug

30 UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Read More Share:

|

Apr

28 UCB Announces PDUFA Date for Bimekizumab

Read More Share:

|

Apr

23 "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Read More Share:

|

Apr

23 UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Read More Share:

|

Categories

Archives

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Choose Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact